Optimizing Multidisciplinary Care for Patients on CDK4/6 Inhibitors

This episode, titled Optimizing Multidisciplinary Care for Patients on CDK4/6 Inhibitors, features breast cancer experts discussing the following critical question:

From your experience, how can multidisciplinary care be optimized when managing patients receiving CDK4/6 inhibitors?

Led by the moderator, the panelist examined optimizing multidisciplinary care for patients receiving CDK4/6 inhibitors involving close coordination among oncologists, pharmacists, nurses, and other healthcare professionals. Regular communication within the care team helps ensure that dosing, adverse event monitoring, and supportive care interventions are consistent and timely. Pharmacists can contribute by reviewing patient medication profiles, identifying potential drug interactions, and providing guidance on toxicity management. Nurses play a key role in patient education, adherence support, and early identification of side effects. Utilizing tools like shared electronic health records (EHR) and care pathways can streamline information flow and facilitate rapid decision-making. By integrating these strategies, the care team can improve patient outcomes, enhance safety, and ensure that therapy remains both effective and tolerable.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Case-Based Discussion: CDK4/6 Inhibitor Use in Early Breast Cancer, panelists will continue their discussion and highlight the management of a 52-year-old postmenopausal woman with stage IIA, hormone receptor–positive, HER2-negative breast cancer, focusing on the pharmacist’s role in patient care. Faculty discuss patient assessment, criteria for CDK4/6 inhibitor eligibility, selection between abemaciclib and ribociclib, and best practices for follow-up and monitoring once therapy is initiated.